Actively Recruiting
Randomized Study of GSK5784283 Felcorekibart Versus Placebo as Add-On Maintenance Therapy in Adults With Chronic Rhinosinusitis With Nasal Polyps
Led by GlaxoSmithKline · Updated on 2026-10-09
218
Participants Needed
4
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of GSK5784283 Felcorekibart as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps CRSwNP. This Phase 3 randomized, double-blind study compares GSK5784283 plus standard of care against placebo plus standard of care to better understand its effects on nasal polyps and related symptoms. Participants will be randomly assigned to receive either GSK5784283 or a placebo alongside their standard treatment. The study lasts for 52 weeks, during which the main focus is on changes in nasal polyp size and nasal obstruction symptoms. Additional assessments include loss of smell, composite symptom scores, CT scan scores, quality of life questionnaires, and time to surgery or additional medication use. Throughout the study, participants will undergo evaluations including endoscopic examinations, symptom scoring, CT scans, and questionnaires at baseline and Week 52. Researchers will monitor asthma control and track the use of corticosteroids or surgical decisions related to nasal polyps. The total participation time spans about one year with safety and symptom monitoring conducted regularly.
CONDITIONS
Brief Title
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here